The PROFID project will develop a clinical decision support tool (risk score) using state-of-the-art methods and extensive clinical data sets from various European areas, which will helps to predict the individual risks of sudden cardiac death and identify those patients after myocardial infarction that will optimally benefit from an ICD. Two parallel randomized clinical trials will be conducted to demonstrate that, compared to current practice of ICD implantation after myocardial infarction, the use of personalized information on the risk of sudden cardiac death can bring significant health benefits to patients and society, while health economic analyses will assess its economic impact on health care systems. A software tool for clinical use of the risk score will be implemented, and a pilot run in 3 European regions with participation of insurance companies and authorities.
The project involves 21 organizations from 11 different European countries, led by Leipzig Heart Institute GmbH, Germany. The project will run for 60 months from January 2020 to December 2024 and is funded by the European Union's Horizon 2020 program. The unique composition of the consortium with key opinion leaders, patient organisations, large hospital chains, payers, policy makers and state authorities across Europe, will ensure implementation into routine clinical practice.
The main goal of the project is to update the guidelines for ESC (the European Society of Cardiology) in order to implement the results of the PROFID study into clinical practice. The project will create a register of patients with atrial fibrillation, where a developed tool will be used to support clinical decision-making during ICD implantation with the calculation of a risk score.
For more information:
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847999.